Photo: Markus Spiske/Unsplash
Brazil could approve a new anti-Covid-19 drug by Tuesday, when federal regulator Anvisa will hold a board meeting to discuss a request by Swiss health conglomerate Roche and Regeneron, a U.S.-based pharmaceutical company.
According to specialized website Pharmaceutical Technology, Roche reports that phase-three trials of Regen-Cov — its antibody cocktail of casirivimab and imdevimab — met its primary objective of reducing the risk of hospitalization or death among high-risk and non-hospitalized Covid-19 patients by 70 percent.
The U.S. Food and Drug Administration gave Regen-Cov emergency approval for use by mild to moderate Covid-19 patients. “This data paves the way for [antibody therapy] Regen-Cov to be used before patients become symptomatic, with a more convenient subcutaneous administration,” said Katharine Bar, co-principal investigator and a professor at the University of Pennsylvania hospital, in a Regeneron press release.
The relationship between farmers and the Luiz Inácio Lula da Silva administration is by no…
Pelé, Ronaldo, Zico, Marta … All of Brazil’s truly immortal sporting icons are footballers, that…
Speaking before a Senate hearing on Tuesday, Chief of Staff Rui Costa admitted that Brazil…
New job market data from the Brazilian Institute of Geography and Statistics (IBGE) show the…
Brazil officially had 5.83 million domestic workers in 2022 — almost the entire population of…
Brazil’s Ministry of Health this month announced a purchase of 12.5 million doses of Moderna’s…